Literature DB >> 30211344

Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.

Ahmet Zehir1, Jaclyn F Hechtman1, Sumit Middha1, Liying Zhang1, Khedoudja Nafa1, Gowtham Jayakumaran1, Donna Wong1, Hyunjae R Kim1, Justyna Sadowska1, Michael F Berger1, Deborah F Delair1, Jinru Shia1, Zsofia Stadler1, David S Klimstra1, Marc Ladanyi1.   

Abstract

PURPOSE: Microsatellite instability (MSI)/mismatch repair (MMR) status is increasingly important in the management of patients with cancer to predict response to immune checkpoint inhibitors. We determined MSI status from large-panel clinical targeted next-generation sequencing (NGS) data across various solid cancer types.
METHODS: The MSI statuses of 12,288 advanced solid cancers consecutively sequenced with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets clinical NGS assay were inferred by using MSIsensor, a program that reports the percentage of unstable microsatellites as a score. Cutoff score determination and sensitivity/specificity were based on MSI polymerase chain reaction (PCR) and MMR immunohistochemistry.
RESULTS: By using an MSIsensor score ≥ 10 to define MSI high (MSI-H), 83 (8%) of 996 colorectal cancers (CRCs) and 42 (16%) of 260 uterine endometrioid cancers (UECs) were MSI-H. Validation against MSI PCR and/or MMR immunohistochemistry performed for 138 (24 MSI-H, 114 microsatellite stable [MSS]) CRCs, and 40 (15 MSI-H, 25 MSS) UECs showed a concordance of 99.4%. MSIsensor also identified 68 MSI-H/MMR-deficient (MMR-D) non-CRC/UECs. Of 9,591 non-CRC/UEC tumors with MSS MSIsensor status, 456 (4.8%) had slightly elevated scores(≥3 and <10) of which 96.6% with available material were confirmed to be MSS by MSI PCR. MSI-H was also detected and confirmed in three non-CRC/UECs with low exonic mutation burden (< 20). MSIsensor correctly scored all 15 polymerase ε ultra-mutated cancers as negative for MSI.
CONCLUSION: MSI status can be reliably inferred by MSIsensor from large-panel targeted NGS data. Concurrent MSI testing by NGS is resource efficient, is potentially more sensitive for MMR-D than MSI PCR, and allows identification of MSI-H across various cancers not typically screened, as highlighted by the finding that 35% (68 of 193) of all MSI-H tumors were non-CRC/ UEC.

Entities:  

Year:  2017        PMID: 30211344      PMCID: PMC6130812          DOI: 10.1200/PO.17.00084

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  17 in total

1.  Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Lynette Cederquist; Emily Chan; Yi-Jen Chen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Peter C Enzinger; Alessandro Fichera; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Christina S Wu; Kristina M Gregory; Deborah Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2017-03       Impact factor: 11.908

2.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

3.  Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing.

Authors:  Jonathan A Nowak; Matthew B Yurgelun; Jacqueline L Bruce; Vanesa Rojas-Rudilla; Dimity L Hall; Priyanka Shivdasani; Elizabeth P Garcia; Agoston T Agoston; Amitabh Srivastava; Shuji Ogino; Frank C Kuo; Neal I Lindeman; Fei Dong
Journal:  J Mol Diagn       Date:  2016-11-15       Impact factor: 5.568

4.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

5.  Classification and characterization of microsatellite instability across 18 cancer types.

Authors:  Ronald J Hause; Colin C Pritchard; Jay Shendure; Stephen J Salipante
Journal:  Nat Med       Date:  2016-10-03       Impact factor: 53.440

6.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

7.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.

Authors:  Jinru Shia
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

8.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.

Authors:  Beifang Niu; Kai Ye; Qunyuan Zhang; Charles Lu; Mingchao Xie; Michael D McLellan; Michael C Wendl; Li Ding
Journal:  Bioinformatics       Date:  2013-12-25       Impact factor: 6.937

9.  Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:  Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

10.  MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations.

Authors:  Mi Ni Huang; John R McPherson; Ioana Cutcutache; Bin Tean Teh; Patrick Tan; Steven G Rozen
Journal:  Sci Rep       Date:  2015-08-26       Impact factor: 4.379

View more
  90 in total

1.  The immunotherapy revolution in genitourinary malignancies.

Authors:  Shruti U Gandhy; Ravi A Madan; Jeanny B Aragon-Ching
Journal:  Immunotherapy       Date:  2020-06-29       Impact factor: 4.196

2.  Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Authors:  Tara E Soumerai; Mark T A Donoghue; Barry S Taylor; David M Hyman; Chaitanya Bandlamudi; Preethi Srinivasan; Matthew T Chang; Dmitriy Zamarin; Karen A Cadoo; Rachel N Grisham; Roisin E O'Cearbhaill; William P Tew; Jason A Konner; Martee L Hensley; Vicky Makker; Paul Sabbatini; David R Spriggs; Tiffany A Troso-Sandoval; Alexandra Snyder Charen; Claire Friedman; Mila Gorsky; Sarah J Schweber; Sumit Middha; Rajmohan Murali; Sarah Chiang; Kay J Park; Robert A Soslow; Marc Ladanyi; Bob T Li; Jennifer Mueller; Britta Weigelt; Ahmet Zehir; Michael F Berger; Nadeem R Abu-Rustum; Carol Aghajanian; Deborah F DeLair; David B Solit
Journal:  Clin Cancer Res       Date:  2018-08-01       Impact factor: 12.531

Review 3.  Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine.

Authors:  Laura Valle; Eduardo Vilar; Sean V Tavtigian; Elena M Stoffel
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

4.  Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.

Authors:  Yasser Ged; Ying-Bei Chen; Andrea Knezevic; Jozefina Casuscelli; Almedina Redzematovic; Renzo G DiNatale; Maria I Carlo; Chung-Han Lee; Darren R Feldman; Sujata Patil; A Ari Hakimi; Paul Russo; Robert J Motzer; Martin H Voss
Journal:  Clin Genitourin Cancer       Date:  2019-04-01       Impact factor: 2.872

5.  Molecular profiling and molecular classification of endometrioid ovarian carcinomas.

Authors:  Paulina Cybulska; Arnaud Da Cruz Paula; Jill Tseng; Mario M Leitao; Ali Bashashati; David G Huntsman; Tayyebeh M Nazeran; Carol Aghajanian; Nadeem R Abu-Rustum; Deborah F DeLair; Sohrab P Shah; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2019-07-21       Impact factor: 5.482

6.  A robust method for the rapid detection of microsatellite instability in colorectal cancer.

Authors:  Lin Zhao; Guangyu Shan; Lei Li; Yang Yu; Gang Cheng; Xu Zheng
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

7.  Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.

Authors:  Caitlin A McIntyre; Sharon A Lawrence; Allison L Richards; Joanne F Chou; Winston Wong; Marinela Capanu; Michael F Berger; Mark T A Donoghue; Kenneth H Yu; Anna M Varghese; David P Kelsen; Wungki Park; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Christine A Iacobuzio-Donahue; Peter J Allen; Eileen M O'Reilly
Journal:  Cancer       Date:  2020-06-23       Impact factor: 6.860

8.  Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.

Authors:  Emiliano Cocco; Jamal Benhamida; Sumit Middha; Ahmet Zehir; Kerry Mullaney; Jinru Shia; Rona Yaeger; Liying Zhang; Donna Wong; Liliana Villafania; Khedoudja Nafa; Maurizio Scaltriti; Alexander Drilon; Leonard Saltz; Alison M Schram; Zsofia K Stadler; David M Hyman; Ryma Benayed; Marc Ladanyi; Jaclyn F Hechtman
Journal:  Cancer Res       Date:  2019-01-14       Impact factor: 12.701

9.  Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.

Authors:  Shyam A Patel; Teri A Longacre; Uri Ladabaum; Alexandra Lebensohn; Albert Y Lin; Sigurdis Haraldsdottir
Journal:  Oncologist       Date:  2018-08-02

10.  Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.

Authors:  François Audenet; Sumit Isharwal; Eugene K Cha; Mark T A Donoghue; Esther N Drill; Irina Ostrovnaya; Eugene J Pietzak; John P Sfakianos; Aditya Bagrodia; Paari Murugan; Guido Dalbagni; Timothy F Donahue; Jonathan E Rosenberg; Dean F Bajorin; Maria E Arcila; Jaclyn F Hechtman; Michael F Berger; Barry S Taylor; Hikmat Al-Ahmadie; Gopa Iyer; Bernard H Bochner; Jonathan A Coleman; David B Solit
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.